Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Attar EC, et al. Among authors: miller kb. Clin Cancer Res. 2008 Mar 1;14(5):1446-54. doi: 10.1158/1078-0432.CCR-07-4626. Clin Cancer Res. 2008. PMID: 18316568 Clinical Trial.
Improved survival for patients with acute myelogenous leukemia.
Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH. Mitus AJ, et al. Among authors: miller kb. J Clin Oncol. 1995 Mar;13(3):560-9. doi: 10.1200/JCO.1995.13.3.560. J Clin Oncol. 1995. PMID: 7884416 Clinical Trial.
Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB. Schenkein DP, et al. Among authors: miller kb. J Clin Oncol. 1994 Nov;12(11):2423-31. doi: 10.1200/JCO.1994.12.11.2423. J Clin Oncol. 1994. PMID: 7964959 Clinical Trial.
Hematology.
Miller KB, Schenkein DP. Miller KB, et al. JAMA. 1993 Jul 14;270(2):216-7. JAMA. 1993. PMID: 8315737 No abstract available.
Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
Schenkein DP, Koc Y, Alcindor T, Stadtmauer EA, Miller KB, Cooper BW, Partridge AH, Lazarus HM. Schenkein DP, et al. Among authors: miller kb. Biol Blood Marrow Transplant. 2000;6(4A):448-55. doi: 10.1016/s1083-8791(00)70037-1. Biol Blood Marrow Transplant. 2000. PMID: 10975514 Clinical Trial.
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D. Kanteti R, et al. Bone Marrow Transplant. 1999 Sep;24(5):473-81. doi: 10.1038/sj.bmt.1701941. Bone Marrow Transplant. 1999. PMID: 10482930 Clinical Trial.
276 results